BOLT Earnings Bolt Biotherapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–24 of 24
| Q2 2026 | 2026-06-30 | -4.57 | 2026-08-11 | 10-Q |
| Q1 2026 | 2026-03-31 | -4.31 | 2026-05-12 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | -3.91 | 2026-03-12 | 10-K |
| FY 2025 | 2025-12-31 | -17.85 | 2026-03-12 | 10-K |
| Q3 2025 | 2025-09-30 | -3.72 | 2025-11-12 | 10-Q |
| Q2 2025 | 2025-06-30 | -4.46 | 2025-08-14 | 10-Q |
| Q1 2025 | 2025-03-31 | -5.76 | 2025-05-12 | 10-Q |
| Q4 2024 (derived) | 2024-12-31 | -8.41 | 2025-03-24 | 10-K |
| FY 2024 | 2024-12-31 | -33.06 | 2025-03-24 | 10-K |
| Q3 2024 | 2024-09-30 | -7.93 | 2024-11-12 | 10-Q |
| Q2 2024 | 2024-06-30 | -11.12 | 2024-08-13 | 10-Q |
| Q1 2024 | 2024-03-31 | -5.60 | 2024-05-14 | 10-Q |
| Q4 2023 (derived) | 2023-12-31 | -9.40 | 2024-03-21 | 10-K |
| FY 2023 | 2023-12-31 | -36.60 | 2024-03-21 | 10-K |
| Q3 2023 | 2023-09-30 | -8.60 | 2023-11-09 | 10-Q |
| Q2 2023 | 2023-06-30 | -9.60 | 2023-08-07 | 10-Q |
| Q1 2023 | 2023-03-31 | -9.00 | 2023-05-11 | 10-Q |
| Q4 2022 (derived) | 2022-12-31 | -10.60 | 2023-03-29 | 10-K |
| FY 2022 | 2022-12-31 | -47.20 | 2023-03-29 | 10-K |
| Q3 2022 | 2022-09-30 | -11.60 | 2022-11-10 | 10-Q |
| Q2 2022 | 2022-06-30 | -12.20 | — | — |
| Q1 2022 | 2022-03-31 | -12.80 | — | — |
| FY 2021 | 2021-12-31 | -59.40 | — | — |
| Q3 2021 | 2021-09-30 | -12.60 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.